Results 31 to 40 of about 288,284 (303)
Prothrombotic immune thrombocytopenia after COVID-19 vaccination
We report five cases of prothrombotic immune thrombocytopenia after exposure to the ChAdOx1 vaccine (AZD1222, Vaxzevria) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients presented 5 to 11 days after first vaccination.
A. Tiede+11 more
semanticscholar +1 more source
. Background. Thrombocytopenia commonly occurs early after liver transplantation. Heparin, usually administered as anticoagulant therapy for thrombosis, a common complication after liver transplantation, may cause heparin-induced thrombocytopenia ...
Naoya Iwasaki+13 more
doaj +1 more source
Romiplostim use in pregnant women with immune thrombocytopenia
Abstract Treatment for immune thrombocytopenia (ITP) in pregnancy is hampered by the lack of fetal safety evidence of maternally‐administered medications. The Pregnancy Surveillance Program (PSP) collected patient information from 2017–2020 for pregnancy, birth outcomes, and adverse events (AEs) for 186 women exposed to romiplostim from 20 days before ...
James B. Bussel+7 more
wiley +1 more source
Risk Factors of Thrombocytopenia After Cardiac Surgery with Cardiopulmonary Bypass
Introduction: Postoperative thrombocytopenia is common in cardiac surgery with cardiopulmonary bypass, and its risk factors are unclear. Methods: This retrospective study enrolled 3,175 adult patients undergoing valve surgeries with cardiopulmonary ...
Shujie Yan+5 more
doaj +1 more source
Cutaneous T‐cell lymphomas: 2023 update on diagnosis, risk‐stratification, and management
Abstract Disease Overview Cutaneous T‐cell lymphomas are a heterogenous group of T‐cell neoplasms involving the skin, the majority of which may be classified as Mycosis Fungoides (MF) or Sézary Syndrome (SS). Diagnosis The diagnosis of MF or SS requires the integration of clinical and histopathologic data.
Alexandra C. Hristov+2 more
wiley +1 more source
The Incidence, Clinical Outcomes, and Risk Factors of Thrombocytopenia in Intra-Abdominal Infection Patients: A Retrospective Cohort Study. [PDF]
Studies on the incidence and risk factors of thrombocytopenia among intra-abdominal infection patients remain absent, hindering efficacy assessments regarding thrombocytopenia prevention strategies.We retrospectively studied 267 consecutively enrolled ...
Qin Wu+9 more
doaj +1 more source
Abstract Patients with relapsed/refractory (R/R) higher‐risk myelodysplastic syndromes (MDS) have a dismal median overall survival (OS) after failing hypomethylating agent (HMA) treatment. There is no standard of care for patients after HMA therapy failure; hence, there is a critical need for effective therapeutic strategies.
Amer M. Zeidan+18 more
wiley +1 more source
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia
Abstract Bruton tyrosine kinase (BTK) inhibitors have taken a central role in the management of patients with Waldenström macroglobulinemia and are the only agents approved by the Food and Drug Administration (FDA) to treat these patients. Although associated with high rates of durable responses, unmet needs with BTK inhibitor therapy include ...
Jorge J. Castillo+4 more
wiley +1 more source
Thrombocytopenia and its association with mortality in patients with COVID‐19
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), which causes novel coronavirus disease 2019 (COVID‐19), is spreading rapidly around the world. Thrombocytopenia in patients with COVID‐19 has not been fully studied.
Xiaobo Yang+6 more
semanticscholar +1 more source
Very rare cases of thrombosis associated with thrombocytopenia have occurred following the vaccination with AstraZeneca COVID‐19 vaccine. The aim of this concise review is to summarize the current knowledge on the epidemiologic and pathogenic mechanisms ...
M. Franchini, G. Liumbruno, M. Pezzo
semanticscholar +1 more source